Status:
COMPLETED
AMAZE™ Asthma Implementation QI Study
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Greater Austin Allergy
Evidera, Inc.
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.
Detailed Description
AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of patients throughout their patient ...
Eligibility Criteria
Inclusion
- \>18 years of age at the time of enrollment
- Clinically confirmed diagnosis of asthma
- Access to a smartphone with internet access with the following requirements: iOS (Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating System 8.0 or newer)
- Able to understand and speak English sufficiently to be able to use the AMAZE™ patient App
- Willingness to participate in a telephone interview and be audio-recorded
- Consenting to participate in the study
Exclusion
- Current diagnosis of active chronic obstructive pulmonary disease (COPD) or any pulmonary diagnosis other than asthma;
- Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, or insufficient knowledge of the English language that, in the opinion of the investigator, would interfere with his or her ability to agree to participate and/or complete the ACT™
Key Trial Info
Start Date :
November 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT04901260
Start Date
November 25 2020
End Date
June 30 2021
Last Update
August 1 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Austin, Texas, United States, 78730
2
Research Site
Austin, Texas, United States, 78746